Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Desmopressin | Vasopressin |
|---|---|---|
| Class | Vasopressin analogue | Posterior pituitary hormone |
| Research category | diabetes insipidus and haemostasis | vasodilatory shock and diabetes insipidus |
| Evidence level | High | High |
| Overall status | Approved (Rx) — diabetes insipidus, nocturia and bleeding disorders | Approved (Rx) — vasodilatory shock |
| FDA | Approved (Rx) | Approved (Rx) |
| EMA | Approved (Rx) | Approved (Rx) |
| WADA | Prohibited — S5 | Check current list |
| Mechanism studied | Desmopressin → Renal V2 receptor → Aquaporin-2 insertion → Water reabsorption | Vasopressin → V1a / V2 receptors → Vasoconstriction & antidiuresis → Blood pressure ↑ |
| Molecular weight | 1,069.2 g/mol | 1,084.2 g/mol |
| Sizes in stock | Not currently listed | Not currently listed |
Where the research overlaps
Both compounds are studied within Endocrine research. Desmopressin is classed as vasopressin analogue, while Vasopressin is posterior pituitary hormone. Evidence is rated high for Desmopressin and high for Vasopressin.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.